The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...

Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.

The study will examine vaccine safety, efficacy and immunity at lower doses. Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical ...